Switch to:
Also traded in: Australia, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
NVGN's Cash to Debt is ranked higher than
97% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.63 vs. NVGN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NVGN' s Cash to Debt Range Over the Past 10 Years
Min: 0.92  Med: 75.40 Max: No Debt
Current: No Debt
Equity to Asset 0.97
NVGN's Equity to Asset is ranked higher than
99% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. NVGN: 0.97 )
Ranked among companies with meaningful Equity to Asset only.
NVGN' s Equity to Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.79 Max: 0.97
Current: 0.97
0.32
0.97
F-Score: 4
Z-Score: 13.31
M-Score: -3.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -10886.52
NVGN's Operating margin (%) is ranked lower than
99% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.82 vs. NVGN: -10886.52 )
Ranked among companies with meaningful Operating margin (%) only.
NVGN' s Operating margin (%) Range Over the Past 10 Years
Min: -10886.52  Med: -203.93 Max: -105.2
Current: -10886.52
-10886.52
-105.2
Net-margin (%) -8021.35
NVGN's Net-margin (%) is ranked lower than
99% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.45 vs. NVGN: -8021.35 )
Ranked among companies with meaningful Net-margin (%) only.
NVGN' s Net-margin (%) Range Over the Past 10 Years
Min: -8583.91  Med: -138.58 Max: 86.52
Current: -8021.35
-8583.91
86.52
ROE (%) -30.92
NVGN's ROE (%) is ranked lower than
86% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. NVGN: -30.92 )
Ranked among companies with meaningful ROE (%) only.
NVGN' s ROE (%) Range Over the Past 10 Years
Min: -269.02  Med: -52.48 Max: 33.98
Current: -30.92
-269.02
33.98
ROA (%) -28.11
NVGN's ROA (%) is ranked lower than
87% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.67 vs. NVGN: -28.11 )
Ranked among companies with meaningful ROA (%) only.
NVGN' s ROA (%) Range Over the Past 10 Years
Min: -143.49  Med: -39.80 Max: 12.06
Current: -28.11
-143.49
12.06
ROC (Joel Greenblatt) (%) -14620.20
NVGN's ROC (Joel Greenblatt) (%) is ranked lower than
98% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.76 vs. NVGN: -14620.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVGN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -18600  Med: -1864.05 Max: -196.47
Current: -14620.2
-18600
-196.47
Revenue Growth (3Y)(%) -100.00
NVGN's Revenue Growth (3Y)(%) is ranked lower than
99% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. NVGN: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVGN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -100  Med: -17.65 Max: 2
Current: -100
-100
2
EBITDA Growth (3Y)(%) -30.70
NVGN's EBITDA Growth (3Y)(%) is ranked lower than
88% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. NVGN: -30.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVGN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -59.5  Med: -20.50 Max: 31.5
Current: -30.7
-59.5
31.5
EPS Growth (3Y)(%) 28.90
NVGN's EPS Growth (3Y)(%) is ranked higher than
81% of the 487 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. NVGN: 28.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVGN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -57.8  Med: -13.70 Max: 28.9
Current: 28.9
-57.8
28.9
» NVGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

NVGN Guru Trades in Q1 2015

Jim Simons 103,200 sh (New)
» More
Q2 2015

NVGN Guru Trades in Q2 2015

Jim Simons 215,600 sh (+108.91%)
» More
Q3 2015

NVGN Guru Trades in Q3 2015

Jim Simons 167,800 sh (-22.17%)
» More
Q4 2015

NVGN Guru Trades in Q4 2015

Jim Simons 139,100 sh (-17.10%)
» More
» Details

Insider Trades

Latest Guru Trades with NVGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.91
NVGN's P/B is ranked higher than
85% of the 934 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.21 vs. NVGN: 0.91 )
Ranked among companies with meaningful P/B only.
NVGN' s P/B Range Over the Past 10 Years
Min: 0.91  Med: 4.00 Max: 13.67
Current: 0.91
0.91
13.67
EV-to-EBIT 0.33
NVGN's EV-to-EBIT is ranked higher than
100% of the 824 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.49 vs. NVGN: 0.33 )
Ranked among companies with meaningful EV-to-EBIT only.
NVGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -41.1  Med: -4.90 Max: 0.1
Current: 0.33
-41.1
0.1
EV-to-EBITDA 0.35
NVGN's EV-to-EBITDA is ranked higher than
100% of the 862 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.85 vs. NVGN: 0.35 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -47.1  Med: -5.00 Max: 0.1
Current: 0.35
-47.1
0.1
Current Ratio 25.11
NVGN's Current Ratio is ranked higher than
97% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.27 vs. NVGN: 25.11 )
Ranked among companies with meaningful Current Ratio only.
NVGN' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 6.35 Max: 25.11
Current: 25.11
0.81
25.11
Quick Ratio 25.11
NVGN's Quick Ratio is ranked higher than
97% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.65 vs. NVGN: 25.11 )
Ranked among companies with meaningful Quick Ratio only.
NVGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 5.46 Max: 25.11
Current: 25.11
0.81
25.11
Days Sales Outstanding 8.20
NVGN's Days Sales Outstanding is ranked higher than
95% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.01 vs. NVGN: 8.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.69  Med: 52.33 Max: 435.3
Current: 8.2
1.69
435.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.00
NVGN's Price/Net Cash is ranked lower than
99.99% of the 281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.83 vs. NVGN: 1.00 )
Ranked among companies with meaningful Price/Net Cash only.
NVGN' s Price/Net Cash Range Over the Past 10 Years
Min: 2.2  Med: 6.76 Max: 23.09
Current: 1
2.2
23.09
Price/Net Current Asset Value 1.00
NVGN's Price/Net Current Asset Value is ranked lower than
99.99% of the 630 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.78 vs. NVGN: 1.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NVGN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.45  Med: 4.77 Max: 19
Current: 1
1.45
19
Price/Tangible Book 1.00
NVGN's Price/Tangible Book is ranked higher than
64% of the 918 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.67 vs. NVGN: 1.00 )
Ranked among companies with meaningful Price/Tangible Book only.
NVGN' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.45  Med: 4.71 Max: 19
Current: 1
1.45
19
Earnings Yield (Greenblatt) (%) 303.00
NVGN's Earnings Yield (Greenblatt) (%) is ranked higher than
100% of the 723 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. NVGN: 303.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVGN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -220.1  Med: 1594.10 Max: 3595.24
Current: 303
-220.1
3595.24

More Statistics

Revenue(Mil) $0
EPS $ -0.58
Beta0.15
Short Percentage of Float0.32%
52-Week Range $1.79 - 9.50
Shares Outstanding(Mil)16.92

Analyst Estimate

Jun16 Jun17 Jun18
Revenue(Mil) 2 4 4
EPS($) -0.50 -0.51 -0.69
EPS without NRI($) -0.50 -0.51 -0.69

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:NRT.Australia, NV9B.Germany, NVGNF.USA,
Novogen Ltd. was incorporated in March 1994 under the jurisdiction of the laws of New South Wales, Australia. The Company is engaged in pharmaceutical drug development. It develops single drug capable of killing both the dominant differentiated cells in a cancer as well as the undifferentiated cancer stem cells at a therapeutic dose. The Company's inaugural drug candidate CS-6 belongs to a new class of drug candidates known as Mitochondrial Electron Transfer Inhibitors that work by depriving the cancer cell of its main energy source. The Company's competitors include pharmaceutical companies and biotechnology companies, as well as universities and public and private research institutions. The activities of the Company are subject to numerous Australian laws and regulations.
» More Articles for NVGN

Headlines

Articles On GuruFocus.com
Novogen (NVGN) Promising Data in Brain Cancer; eFuture Information Technology (EFUT) and NeoPhotonic Mar 04 2015 

More From Other Websites
Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed Feb 05 2016
Letter to Shareholders from CEO James Garner Jan 31 2016
Novogen appoints new CEO Dec 09 2015
Novogen Appoints Dr James Garner as Chief Executive Officer Dec 09 2015
NOVOGEN LTD Financials Dec 08 2015
Novogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial Nov 23 2015
Novogen Patent Covering Cantrixil and Trilexium Accepted in Australia Nov 11 2015
Preclinical Studies Justify Mode of Delivery and Dosing Regimen for Anisina Nov 10 2015
Novogen Applies for Long-Term Options Listing on ASX Sep 30 2015
Novogen Applies for Long-term Options Listing Sep 29 2015
Novogen (NVGN) Conducts Scientific Review of R&D Program Aug 31 2015
Novogen Announces The Outcome Of A Comprehensive Science Review Aug 30 2015
Novogen to review pre-clinical programs Jul 30 2015
Newly Appointed Acting CEO Outlines Immediate Plans for Novogen Jul 29 2015
Novogen to review its pre-clinical trials Jul 29 2015
Former CEO: Novogen in sound position Jul 21 2015
Novogen Appoints Iain Ross as Acting CEO and Re-appoints Him to the Board Jul 21 2015
Novogen shares tumble Jul 21 2015
Novogen chief executive resigns Jul 21 2015
Anisina Receives Orphan Drug Designation from FDA for Neuroblastoma Jul 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK